Searching for a retatrutide dosage calculator usually means you want one thing: a simple way to understand retatrutide doses, dose escalation and what the numbers from clinical trials actually mean.
There is a catch. Retatrutide is still an investigational medicine. It has not been approved for routine medical use, so there is currently no official patient dosing calculator that can tell you what dose you should take. Lilly states that retatrutide remains available through clinical trials and warns against using products sold as retatrutide outside a Lilly-sponsored trial.
That doesn’t mean the numbers are impossible to understand. Published clinical trials provide useful information about doses researchers have studied, how escalation was handled, and how average weight loss differed between treatment groups. This guide turns that information into a practical retatrutide dosage calculator guide without confusing research data with a personal prescription.
Retatrutide Dosage Calculator
Use a research calculator to answer questions such as:
- Which retatrutide doses have been studied?
- What target doses were evaluated in clinical trials?
- How does a percentage weight reduction translate into kilograms or pounds?
- How many weeks were participants treated?
- What percentage of body weight did study participants lose?
A responsible calculator should not tell you how much retatrutide to inject.
Educational Retatrutide Trial Calculator
Starting body weight: Enter your weight.
Research weight-loss percentage: Enter a percentage reported in a clinical trial.
Estimated weight change:
Starting weight × percentage weight loss ÷ 100
Estimated weight after that percentage reduction:
Starting weight − estimated weight change
For example, someone weighing 100 kg who experiences a hypothetical 20% reduction would lose 20 kg and reach 80 kg.
That is simply mathematics. It does not predict what an individual will lose on retatrutide.
What Is Retatrutide?
Retatrutide, also known as LY3437943, is an investigational medicine developed by Eli Lilly. It is different from conventional GLP-1 medicines because it activates three hormone receptors: GIP, GLP-1 and glucagon.
This triple-receptor activity is one reason retatrutide has attracted so much attention in obesity research.
Clinical trials have investigated retatrutide in people with obesity, overweight and related conditions. The results have shown substantial average weight reductions, but the medicine is still being evaluated and has not received regulatory approval.
Retatrutide Dosage: What Has Been Studied?
This is where online searches can become confusing.
People often see numbers such as 1 mg, 4 mg, 8 mg, 9 mg and 12 mg and assume they represent an approved dosing schedule. They do not.
They represent doses or target doses investigated in different clinical trials.
In a Phase 2 obesity study published in the New England Journal of Medicine, researchers evaluated once-weekly retatrutide at 1 mg, 4 mg, 8 mg and 12 mg. Some groups assigned to higher doses started at 2 mg or 4 mg and gradually increased their dose during the study.
Later Phase 3 research evaluated 4 mg, 9 mg and 12 mg target doses in several study populations. For example, Lilly’s TRIUMPH-1 trial evaluated adults with obesity or overweight and at least one weight-related complication, without diabetes.
The distinction between studied dose and approved dose is essential.
There is currently no approved retatrutide dose for routine patient treatment.
Retatrutide Dose Escalation Explained
Dose escalation means researchers do not necessarily give participants their eventual target dose immediately.
Instead, some clinical-trial protocols used lower starting doses followed by increases at defined intervals.
Why?
One major reason is tolerability.
In the Phase 2 obesity trial, gastrointestinal adverse events such as nausea, diarrhea and vomiting were among the most common adverse events. Researchers reported that these effects were dose-related and that using a lower starting dose partially reduced gastrointestinal problems.
This is one reason you should not take a trial schedule and turn it into a personal self-treatment plan.
A research protocol is designed around eligibility criteria, monitoring and predefined safety procedures.
Retatrutide Clinical Trial Doses at a Glance
| Study | Population | Research doses/targets | Main result |
|---|---|---|---|
| Phase 2 | Adults with obesity/overweight | 1, 4, 8 and 12 mg | Up to 24.2% mean weight reduction at 48 weeks in the 12 mg group |
| TRIUMPH-1 | Obesity/overweight without diabetes | 4, 9 and 12 mg | Up to 28.3% mean weight reduction at 80 weeks |
| TRIUMPH-2 | Obesity/overweight with type 2 diabetes | 4, 9 and 12 mg | Up to 20.8% mean weight reduction at 80 weeks |
| TRIUMPH-3 | Severe obesity with cardiovascular disease | 9 and 12 mg | Up to 22.6% mean weight reduction at 80 weeks |
The doses in this table describe clinical research, not recommended self-treatment. Phase 3 results reported by Lilly are topline results and should not be treated as an approved prescribing schedule.
How Much Weight Did People Lose With Retatrutide?
This is one of the biggest reasons people search for retatrutide.
The Phase 2 study produced substantial average weight reductions over 48 weeks. The reported least-squares mean change was:
- 1 mg: −8.7%
- 4 mg: −17.1% when the 4 mg groups were combined
- 8 mg: −22.8% when the 8 mg groups were combined
- 12 mg: −24.2%
The placebo group had a −2.1% change.
More recent Phase 3 results have shown further substantial average reductions.
In TRIUMPH-1, Lilly reported average weight reductions of 19.0% with 4 mg, 25.9% with 9 mg and 28.3% with 12 mg at 80 weeks.
Those numbers are averages across study participants. They are not guarantees.
Retatrutide Weight Loss Calculator
You can use a simple percentage calculation to understand what a reported trial percentage would mean mathematically.
Formula:
Weight loss = Starting weight × reported percentage ÷ 100
For example:
If starting weight = 100 kg
And reported reduction = 25%
Then:
100 × 25 ÷ 100 = 25 kg
Estimated remaining weight:
100 − 25 = 75 kg
Again, this illustrates the mathematics behind a published percentage. It does not predict your individual response to retatrutide.
Retatrutide 12 mg Weight Loss: What the Research Shows
The 12 mg dose has received considerable attention because higher-dose groups produced larger average reductions in several trials.
In the Phase 2 study, the 12 mg group had a reported 24.2% mean weight reduction at 48 weeks.
In TRIUMPH-1, participants receiving the 12 mg target dose had an average 28.3% reduction at 80 weeks. Lilly also reported that 45.3% of participants in that group achieved at least 30% weight loss.
These results are impressive, but a higher research dose should not automatically be interpreted as a better choice for an individual.
Clinical trials evaluate efficacy and safety together.
Retatrutide 9 mg vs 12 mg
The difference between 9 mg and 12 mg has also become a popular search topic because both doses have been studied in Phase 3 trials.
In TRIUMPH-1, Lilly reported:
| Target dose | Average weight reduction at 80 weeks |
|---|---|
| 4 mg | 19.0% |
| 9 mg | 25.9% |
| 12 mg | 28.3% |
| Placebo | 2.2% |
The trial started with participants at lower doses and used escalation toward their assigned target dose.
The figures show the study results. They do not establish that everyone should work toward the highest dose.
Retatrutide vs. Semaglutide vs. Tirzepatide
Retatrutide is often compared with semaglutide and tirzepatide because all three have attracted attention in obesity treatment.
But they are not the same medicine.
Retatrutide is an investigational GIP/GLP-1/glucagon triple agonist. Tirzepatide activates GIP and GLP-1 receptors, while semaglutide is a GLP-1 receptor agonist.
That difference in mechanism is one reason researchers are interested in studying retatrutide.
However, comparisons between medicines should account for the trial population, treatment duration, dose, study design and endpoints. Comparing one headline percentage with another can produce a misleading picture.
Is Retatrutide FDA Approved?
No.
As of September 2026, retatrutide has not been approved by the FDA or another regulatory agency for routine patient treatment. Lilly says the medicine remains investigational and is being evaluated in Phase 3 studies. Lilly announced in July 2026 that it planned to submit a Biologics License Application to the FDA in the first quarter of 2027.
That means there is currently no FDA-approved retatrutide prescribing label that establishes a routine patient dosage.
This distinction should appear prominently on any website publishing retatrutide dosage information.
Can You Buy Retatrutide Online?
Be careful with websites selling products described as retatrutide.
Lilly states that retatrutide has not been approved and warns that products sold illegally may contain unknown ingredients, contaminants, impurities, too much or too little active ingredient, or an entirely different ingredient.
A product being advertised online does not establish that it is genuine, sterile or safe.
If you are considering an investigational treatment, discuss the option with a qualified healthcare professional and use legitimate clinical-trial or regulated medical channels.
Common Retatrutide Calculator Mistakes
Mistake #1: Treating a clinical-trial dose as a prescription
A research dose tells you what investigators studied. It does not tell you what you personally should take.
Mistake #2: Assuming dose equals weight
Retatrutide trial dosing is not simply a “mg per kilogram” calculation.
Do not assume that your body weight automatically determines a retatrutide dose.
Mistake #3: Looking only at the highest weight-loss number
The largest percentage reduction often attracts the most attention, but clinical research also evaluates adverse events, tolerability and other outcomes.
Mistake #4: Ignoring the study duration
A 48-week result and an 80-week result are not directly interchangeable.
Always check how long participants were followed.
Mistake #5: Assuming average weight loss is guaranteed
A trial average describes a population.
Individual responses vary.
Mistake #6: Using an online calculator to decide an injection dose
A calculator cannot assess your medical history, current medications, contraindications or side effects.
For an investigational medicine, this limitation is even more significant.
What Should a Good Retatrutide Calculator Show?
If you are evaluating a calculator online, look for these features:
- Clear explanation that retatrutide is investigational
- Clinical-trial references
- Study-specific dose information
- Treatment duration
- Weight-loss percentage calculations
- Clear separation between research data and medical advice
- Updated information
- No claims that the calculator can prescribe a personal dose
Avoid calculators that simply ask for your weight and immediately produce an injection dose without explaining where the number came from.
Frequently Asked Questions
1. What is the retatrutide dosage?
There is currently no FDA-approved routine patient dosage for retatrutide. Clinical trials have studied different doses, including 1 mg, 4 mg, 8 mg, 9 mg and 12 mg depending on the study and target-dose design.
2. What is the starting dose of retatrutide in clinical trials?
Different studies have used different protocols. In the Phase 2 obesity trial, some participants assigned to higher target doses began at 2 mg or 4 mg and then underwent gradual escalation.
That research protocol should not be interpreted as an instruction for personal use.
3. How often is retatrutide taken?
Clinical studies have evaluated retatrutide as a once-weekly subcutaneous treatment. The frequency used in a clinical trial does not mean the medicine is approved for routine self-administration.
4. How much weight can you lose with retatrutide?
Clinical-trial results have reported substantial average weight reductions. In Phase 2, the 12 mg group had a reported 24.2% mean reduction at 48 weeks. In TRIUMPH-1, the 12 mg group had a reported 28.3% mean reduction at 80 weeks.
Individual results can differ substantially.
5. Is retatrutide available by prescription?
Retatrutide has not received regulatory approval for routine patient treatment as of September 2026. Lilly states that it remains investigational.
6. Is a retatrutide dosage calculator safe to use?
An educational calculator can be useful for understanding clinical-trial data and performing mathematical calculations. It should not be used to determine a personal injection dose.
7. What is the difference between 9 mg and 12 mg retatrutide?
Both target doses have been studied in Phase 3 research. In TRIUMPH-1, Lilly reported average weight reductions of 25.9% with 9 mg and 28.3% with 12 mg at 80 weeks.
Those are study results, not individual treatment recommendations.
8. Why is retatrutide so popular for weight loss?
Interest has largely come from clinical-trial results showing substantial average reductions in body weight. Retatrutide’s triple-receptor mechanism has also generated significant research interest.
9. Is retatrutide the same as Ozempic or Mounjaro?
No. Retatrutide has a different receptor mechanism from semaglutide and tirzepatide. Retatrutide activates GIP, GLP-1 and glucagon receptors and remains investigational.
10. Can I calculate my personal retatrutide dose from my weight?
No. Body weight alone is not an appropriate basis for determining a personal retatrutide dose, and there is currently no approved retatrutide dosing label for routine use.
A Better Way to Use Retatrutide Dosage Information
The most useful retatrutide dosage calculator isn’t one that gives you a number and tells you to inject it.
It’s one that helps you understand the numbers behind the research.
Retatrutide has produced substantial weight-loss results in clinical trials, including average reductions approaching 30% in some Phase 3 study groups. But those findings exist within controlled research protocols, not as a license for self-treatment.
As research continues and regulatory decisions approach, dosing information may change. For now, use calculators to understand clinical-trial data, percentages and research protocols, and rely on qualified healthcare professionals for decisions about your own treatment.
If you’re considering a new diet, medication or weight-management routine, speak with a qualified healthcare professional before starting it.
